Table 2.
1H-MRS neurometabolite concentrations of participants treated with either baclofen (30–75 mg dose) or placebo.
| Metabolites | Placebo | Baclofen 30–75 mg |
|---|---|---|
| Full sample, n | 11 | 20 |
| GABA+ | 0.55 ± 0.04 | 0.53 ± 0.09 |
| Glu/Cr | 1.50 ± 0.07 | 1.47 ± 0.09 |
| GSH/Cr* | 0.43 ± 0.03 | 0.45 ± 0.03 |
| NAA/Cr* | 1.40 ± 0.13 | 1.47 ± 0.11 |
| NAAG/Cr | 0.14 ± 0.05 | 0.13 ± 0.07 |
| Recent alcohol consumption∧, n (%) | 5 (46) | 4 (20) |
| GABA+ | 0.53 ± 0.04 | 0.59 ± 0.05 |
| Glu/Cr | 1.47 ± 0.06 | 1.55 ± 0.08 |
| GSH/Cr* | 0.42 ± 0.02 | 0.47 ± 0.01 |
| NAA/Cr* | 1.38 ± 0.09 | 1.54 ± 0.05 |
| NAAG/Cr | 0.12 ± 0.03 | 0.09 ± 0.05 |
Data represent raw means ± SD.
∧
in previous 24 h before scanning, Y/N.
*
p < 0.05, comparing baclofen (30–75 mg) vs. placebo. Patients were previously treated with either BAC or PL for an average of 17 days and were scanned approximately 120 min following administration of BAC or PL.